Medicine Overview

Indication

Know Medicine, Follow Guideline

Adult Dose

Clinical InformationAdministration Information
Indication: Prophylaxis of invasive fungal infections
Age: Adult
Dose: Delayed-release tablet – 300 mg
Frequency: twice daily on the 1st day, then once daily thereafter
Note: Treatment duration is based on recovery from neutropenia or immunosuppression
Indication: Prophylaxis of invasive fungal infections
Age: Adult
Dose: Oral suspension – 200 mg
Frequency: three times daily
Note: Treatment duration is based on recovery from neutropenia or immunosuppression

Child Dose

Clinical InformationAdministration Information
Indication: Invasive Aspergillus and Candida Infections
Age: less than 18 years
Condition: severely immunocompromised
Dose: Intravenous – Dose not established
Note: Safety and efficacy not established
Indication: Invasive Aspergillus and Candida Infections
Age: less than 13 years
Condition: severely immunocompromised
Dose: Tablet and Oral suspension – Dose not established
Note: Safety and efficacy not established

Renal Dose

Clinical InformationAdministration Information
Condition: Moderate-to-severe renal impairment (estimated glomerular filtration rate less than 50 mL/min)
Dose: Intravenous – Dose not specified
Note: Avoid intravenous administration unless benefit/risk assessment justifies use. Accumulation of the intravenous vehicle, SBECD, is expected to occur. Serum creatinine levels should be closely monitored; if increases occur, consideration should be given to changing to oral posaconazole therapy.
Condition: Severe renal impairment
Dose: Tablets or Oral suspension – Dose not specified
Note: Variability of systemic exposure with tablets or oral suspension observed. Monitored closely for breakthrough fungal infections.
Administration
  • Tablets: Take with food
  • Oral suspension: Take with meal or nutritional supplement
Side Effect

Drug Interaction

Drug NameRisk Factors
Efavirenz, fosamprenavir, cimetidine, esomeprazole, metoclopramide, phenytoin, rifabutin
Decreased plasma concentrations
Ritonavir, atazanavir
May increase plasma concentration

Disease Interaction

Disease NameRisk Factors
Hypersensitivity
Risk of severe allergic reaction

Pregnancy

Lactation
Special Use
Precaution
Overdose
Pharmacology
Storage
Store below 25°C. Keep out of the reach of children.

Data Sources

Clinical & regulatory information on this page is compiled from the following government sources:

DISCLAIMER: This drug information content is provided for informational purposes only and is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Patients should always consult their physician with any questions regarding a medical condition and to obtain medical advice and treatment.